188 related articles for article (PubMed ID: 34617262)
1. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling.
Gerhart JG; Carreño FO; Edginton AN; Sinha J; Perrin EM; Kumar KR; Rikhi A; Hornik CP; Harris V; Ganguly S; Cohen-Wolkowiez M; Gonzalez D;
Clin Pharmacokinet; 2022 Feb; 61(2):307-320. PubMed ID: 34617262
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.
Thompson EJ; Wu H; Maharaj A; Edginton AN; Balevic SJ; Cobbaert M; Cunningham AP; Hornik CP; Cohen-Wolkowiez M
Clin Pharmacokinet; 2019 Jul; 58(7):887-898. PubMed ID: 30840200
[TBL] [Abstract][Full Text] [Related]
3. Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations.
Gerhart JG; Balevic S; Sinha J; Perrin EM; Wang J; Edginton AN; Gonzalez D
Front Pharmacol; 2022; 13():818726. PubMed ID: 35359853
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.
Autmizguine J; Melloni C; Hornik CP; Dallefeld S; Harper B; Yogev R; Sullivan JE; Atz AM; Al-Uzri A; Mendley S; Poindexter B; Mitchell J; Lewandowski A; Delmore P; Cohen-Wolkowiez M; Gonzalez D;
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084742
[TBL] [Abstract][Full Text] [Related]
5. Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.
Harskamp-van Ginkel MW; Hill KD; Becker KC; Testoni D; Cohen-Wolkowiez M; Gonzalez D; Barrett JS; Benjamin DK; Siegel DA; Banks P; Watt KM;
JAMA Pediatr; 2015 Jul; 169(7):678-85. PubMed ID: 25961828
[TBL] [Abstract][Full Text] [Related]
6. Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.
Gerhart JG; Carreño FO; Loop MS; Lee CR; Edginton AN; Sinha J; Kumar KR; Kirkpatrick CM; Hornik CP; Gonzalez D;
Clin Pharmacol Ther; 2022 Aug; 112(2):391-403. PubMed ID: 35451072
[TBL] [Abstract][Full Text] [Related]
7. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity.
Gerhart JG; Carreño FO; Ford JL; Edginton AN; Perrin EM; Watt KM; Muller WJ; Atz AM; Al-Uzri A; Delmore P; Gonzalez D;
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):778-791. PubMed ID: 35491971
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: The role of weight-based dosing.
Cox KK; Alexander B; Livorsi DJ; Heintz BH
J Infect; 2017 Dec; 75(6):486-492. PubMed ID: 28919346
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
10. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.
Hornik CP; Wu H; Edginton AN; Watt K; Cohen-Wolkowiez M; Gonzalez D
Clin Pharmacokinet; 2017 Nov; 56(11):1343-1353. PubMed ID: 28290120
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.
Chin TW; Vandenbroucke A; Fong IW
Antimicrob Agents Chemother; 1995 Jan; 39(1):28-33. PubMed ID: 7695325
[TBL] [Abstract][Full Text] [Related]
12. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
Edginton AN; Shah B; Sevestre M; Momper JD
Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.
Safrin S; Finkelstein DM; Feinberg J; Frame P; Simpson G; Wu A; Cheung T; Soeiro R; Hojczyk P; Black JR
Ann Intern Med; 1996 May; 124(9):792-802. PubMed ID: 8610948
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.
Ganguly S; Edginton AN; Gerhart JG; Cohen-Wolkowiez M; Greenberg RG; Gonzalez D;
Clin Pharmacokinet; 2021 Dec; 60(12):1591-1604. PubMed ID: 34155614
[TBL] [Abstract][Full Text] [Related]
17. Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.
Hall RG; Pasipanodya JG; Meek C; Leff RD; Swancutt M; Gumbo T
CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):674-681. PubMed ID: 27869362
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.
Pressiat C; Mea-Assande V; Yonaba C; Treluyer JM; Dahourou DL; Amorissani-Folquet M; Blanche S; Eboua F; Ye D; Lui G; Malateste K; Zheng Y; Leroy V; Hirt D;
Br J Clin Pharmacol; 2017 Dec; 83(12):2729-2740. PubMed ID: 28800382
[TBL] [Abstract][Full Text] [Related]
19. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
[TBL] [Abstract][Full Text] [Related]
20. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy.
Maharaj AR; Wu H; Hornik CP; Arrieta A; James L; Bhatt-Mehta V; Bradley J; Muller WJ; Al-Uzri A; Downes KJ; Cohen-Wolkowiez M
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):199-218. PubMed ID: 32323049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
